上海交通大学学报（医学版）

上海交通大学学报（医学版） >

2021 , Vol. 41 >Issue 8: 1041 - 1045

DOI: https://doi.org/10.3969/j.issn.1674-8115.2021.08.007

论著 · 临床研究

精神分裂症与抑郁症失匹配负波异常的对照研究

  • 沈梦婷 ,
  • 张选红 ,
  • 钱禛颖 ,
  • 李惠 ,
  • 盛建华 ,
  • 王继军 ,
  • 唐莺莹
展开
  • 上海交通大学医学院附属精神卫生中心脑电影像室，上海 200030
沈梦婷(1996—)，女，硕士生；电子信箱：15258410298@sjtu.edu.cn。
张选红，电子信箱：zhangxuanhong403@163.com。#为共同通信作者。
唐莺莹，电子信箱：yytang0522@gmail.com

网络出版日期: 2021-08-13

基金资助

国家自然科学基金(81671332);上海市自然科学基金(17ZR1424700)

收起

Comparison of mismatch negativity in patients with schizophrenia and depression

  • Meng-ting SHEN ,
  • Xuan-hong ZHANG ,
  • Zhen-ying QIAN ,
  • Hui LI ,
  • Jian-hua SHENG ,
  • Ji-jun WANG ,
  • Ying-ying TANG
Expand
  • Department of EEG and Neuroimaging, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China
ZHANG Xuan-hong, E-mail: zhangxuanhong403@163.com. #Co-corresponding authors.
TANG Ying-ying, E-mail: yytang0522@gmail.com

Online published: 2021-08-13

Supported by

National Natural Science Foundation of China(81671332);National Natural Science Foundation of Shanghai(7ZR1424700)

Fold

摘要

目的·比较精神分裂症首发患者和抑郁症患者的失匹配负波（mismatch negativity，MMN），及其与临床特征的相关性，探讨前注意加工异常在精神分裂症和抑郁症病理机制中的作用。方法·纳入2014年1月—2016年12月于上海交通大学医学院附属精神卫生中心门诊就诊的精神分裂症首发患者20例和抑郁症患者19例，并同时招募健康对照者，用阳性和阴性精神症状评定量表（Positive and Negative Syndrome Scale，PANSS）评估精神分裂症首发患者的症状，用汉密尔顿抑郁量表（Hamilton Depression Scale，HAMD）、汉密尔顿焦虑量表（Hamilton Anxiety Scale，HAMA）评估抑郁症患者的症状。所有受试者完成MMN检测和临床量表的评估。对频率偏差刺激（frequency MMN，FMMN）和持续时间偏差刺激（duration MMN，DMMN）的波幅和潜伏期采用重复测量方差分析，组间因素为组别，中线导联的组内因素为电极（Fz、Fcz），左右半球导联的组内因素为区域（F、Fc）和左右半球（左：1；右：2），性别为协变量。DMMN、FMMN与临床特征之间的相关性采用偏相关分析。结果·① 精神分裂症组DMMN波幅［（-2.70±2.46）μV］较抑郁症组［（-5.06±0.46）μV］和正常对照组［（-5.15±0.43）μV］降低（均P≤0.001）。3组的DMMN潜伏期在前额叶中线和左右半球导联处差异均无统计学意义（均P>0.05）。② FMMN波幅在中线导联处组间差异无统计学意义（P >0.05），在左右半球导联处组间差异有统计学意义（P =0.040）。3组的FMMN潜伏期在前额叶中线和左右半球导联处差异均无统计学意义（均P >0.05）。③ 精神分裂症组F2、Fz 电极处的DMMN波幅与PANSS一般精神病理症状评分呈负相关（F2：P=0.042；Fz：P=0.032）。抑郁症组MMN潜伏期及波幅与临床特征均无相关性。结论·精神分裂症首发患者有DMMN波幅的异常，而抑郁症患者DMMN波幅正常，提示DMMN波幅可能为鉴别精神分裂症和抑郁症的生物学指标。

关键词： 精神分裂症; 抑郁症; 失匹配负波; 事件相关电位

本文引用格式

沈梦婷 , 张选红 , 钱禛颖 , 李惠 , 盛建华 , 王继军 , 唐莺莹 . 精神分裂症与抑郁症失匹配负波异常的对照研究[J]. 上海交通大学学报（医学版）, 2021 , 41(8) : 1041 -1045 . DOI: 10.3969/j.issn.1674-8115.2021.08.007

Abstract

Objective

·To compare the difference of mismatch negativity (MMN) between first-episode schizophrenia and depression and its correlation with clinical characteristics, and explore the role of pre-attention processing in the mechanisms of schizophrenia and depression.

Methods

·Twenty patients with schizophrenia and 19 patients with depression were selected in the outpatient department of Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine from January 2014 to December 2016. Healthy controls were also recruited. The Positive and Negative Syndrome Scale (PANSS) was used to measure the clinical symptoms of schizophrenia. Hamilton Depression Scale (HAMD) and Hamilton Anxiety Scale (HAMA) were used to measure the clinical symptoms of depression. All patients and healthy controls completed MMN detection and clinical scale assessments. The amplitudes and latencies of duration MMN (DMMN) and frequency MMN (FMMN) were analyzed by repeated measures analysis of variance with group as the between-group factors. The midline electrodes (Fz, Fcz) were used as the with-in group factor; meanwhile, region (F, Fc) and laterality (1 for left, 2 for right) were used as the within-group factors for lateral electrodes and the factor sex was used as covariate. Partial correlations was performed to find the correlation between MMN and clinical characteristics.

Results

·① The amplitude of DMMN in patients with schizophrenia 2 for [(-2.70±2.46) μV)] was lower than that in patients with depression [(-5.06±0.46) μV] and healthy controls [(-5.15±0.43) μV] (both P≤0.001). No significant group differences of DMMN latency were observed at midline or lateral electrodes (All P>0.05). ② There was no significant group difference of FMMN amplitudes at midline electrodes (P>0.05) but a significant between-group difference at lateral electrodes (P=0.040). No significant group differences of FMMN latency were observed at midline or lateral electrodes (All P>0.05). ③ There was a significant correlation between DMMN amplitudes at F2 (P=0.042) or Fz (P=0.032) and general scores of PANSS in schizophrenia patients. There was no correlation in depression patients.

Conclusion

·Abnormality of DMMN exists in the patients with first episode schizophrenia but not in the patients with depression, suggesting that DMMN amplitudes may work as a biological marker to distinguish schizophrenia and depression.

Key words： schizophrenia; depression; mismatch negativity; event-related potential

参考文献

1 Javitt DC, Spencer KM, Thaker GK, et al. Neurophysiological biomarkers for drug development in schizophrenia[J]. Nat Rev Drug Discov, 2008, 7(1): 68-83.
2 Michie PT, Malmierca MS, Harms L, et al. Understanding the neurobiology of MMN and its reduction in schizophrenia[J]. Biol Psychol, 2016, 116: 1-3.
3 Adell A. Brain NMDA receptors in schizophrenia and depression[J]. Biomolecules, 2020, 10(6): 947.
4 Wu JQ, Green MJ, Gardiner EJ, et al. Altered neural signaling and immune pathways in peripheral blood mononuclear cells of schizophrenia patients with cognitive impairment: a transcriptome analysis[J]. Brain Behav Immun, 2016, 53: 194-206.
5 Harada E, Satoi Y, Kikuchi T, et al. Residual symptoms in patients with partial versus complete remission of a major depressive disorder episode: patterns of painful physical symptoms in depression[J]. Neuropsychiatr Dis Treat, 2016, 12: 1599-1607.
6 Donaldson KR, Novak KD, Dan FT, et al. Associations of mismatch negativity with psychotic symptoms and functioning transdiagnostically across psychotic disorders[J]. J Abnorm Psychol, 2020, 129(6): 570-580.
7 Koshiyama D, Kirihara K, Tada M, et al. Reduced auditory mismatch negativity reflects impaired deviance detection in schizophrenia[J]. Schizophr Bull, 2020, 46(4): 937-946.
8 Atkinson RJ, Michie PT, Schall U. Duration mismatch negativity and P3a in first-episode psychosis and individuals at ultra-high risk of psychosis[J]. Biol Psychiatry, 2012, 71(2): 98-104.
9 Chen J, Zhang Y, Wei DH, et al. Neurophysiological handover from MMN to P3a in first-episode and recurrent major depression[J]. J Affect Disord, 2015, 174: 173-179.
10 Toyomaki A, Kusumi I, Matsuyama T, et al. Tone duration mismatch negativity deficits predict impairment of executive function in schizophrenia[J]. Prog Neuropsychopharmacol Biol Psychiatry, 2008, 32(1): 95-99.
11 Magno E, Yeap S, Thakore JH, et al. Are auditory-evoked frequency and duration mismatch negativity deficits endophenotypic for schizophrenia? High-density electrical mapping in clinically unaffected first-degree relatives and first-episode and chronic schizophrenia[J]. Biol Psychiatry, 2008, 64(5): 385-391.
12 Bonetti L, Haumann NT, Vuust P, et al. Risk of depression enhances auditory Pitch discrimination in the brain as indexed by the mismatch negativity[J]. Clin Neurophysiol, 2017, 128(10): 1923-1936.
13 Anaya C, Torrent C, Caballero FF, et al. Cognitive reserve in bipolar disorder: relation to cognition, psychosocial functioning and quality of life[J]. Acta Psychiatr Scand, 2016, 133(5): 386-398.
14 Nagai T, Kirihara K, Tada M, et al. Reduced mismatch negativity is associated with increased plasma level of glutamate in first-episode psychosis[J]. Sci Rep, 2017, 7(1): 2258.
15 顾君, 徐清, 刘晓伟, 等. 抑郁症与单纯型精神分裂症鉴别诊断中定量脑电图的应用价值研究[J]. 中国全科医学, 2014, 17(20): 2312-2316.
16 Koshiyama D, Kirihara K, Tada M, et al. Association between mismatch negativity and global functioning is specific to duration deviance in early stages of psychosis[J]. Schizophr Res, 2018, 195: 378-384.
17 Koshiyama D, Kirihara K, Tada M, et al. Duration and frequency mismatch negativity shows no progressive reduction in early stages of psychosis[J]. Schizophr Res, 2017, 190: 32-38.
18 Murphy TK, Haigh SM, Coffman BA, et al. Mismatch negativity and impaired social functioning in long-term and in first episode schizophrenia spectrum psychosis[J]. Front Psychiatry, 2020, 11: 544.
19 Pilowsky LS, Bressan RA, Stone JM, et al. First in vivo evidence of an NMDA receptor deficit in medication-free schizophrenic patients[J]. Mol Psychiatry, 2006, 11(2): 118-119.
20 Qiao ZX, Yu YM, Wang L, et al. Impaired pre-attentive change detection in major depressive disorder patients revealed by auditory mismatch negativity[J]. Psychiatry Res, 2013, 211(1): 78-84.
21 Kaut O, Schmitt I, Hofmann A, et al. Aberrant NMDA receptor DNA methylation detected by epigenome-wide analysis of hippocampus and prefrontal cortex in major depression[J]. Eur Arch Psychiatry Clin Neurosci, 2015, 265(4): 331-341.
22 Jaso BA, Niciu MJ, Iadarola ND, et al. Therapeutic modulation of glutamate receptors in major depressive disorder[J]. Curr Neuropharmacol, 2017, 15(1): 57-70.
23 Raith H, Schuelert N, Duveau V, et al. Differential effects of traxoprodil and S-ketamine on quantitative EEG and auditory event-related potentials as translational biomarkers in preclinical trials in rats and mice[J]. Neuropharmacology, 2020, 171: 108072.
24 Salisbury DF, Shafer AR, Murphy TK, et al. Pitch and duration mismatch negativity and heschl's gyrus volume in first-episode schizophrenia-spectrum individuals[J]. Clin EEG Neurosci, 2020, 51(6): 359-364.
25 Mu Z, Chang Y, Xu J, et al. Pre-attentive dysfunction of musical processing in major depressive disorder: a mismatch negativity study[J]. J Affect Disord, 2016, 194: 50-56.
26 He W, Chai H, Zheng LL, et al. Mismatch negativity in treatment-resistant depression and borderline personality disorder[J]. Prog Neuropsychopharmacol Biol Psychiatry, 2010, 34(2): 366-371.
27 Bissonnette JN, Francis AM, Hull KM, et al. MMN-indexed auditory change detection in major depressive disorder[J]. Clin EEG Neurosci, 2020, 51(6): 365-372.
Options
文章导航

/

〈 〉